The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma.
Dean Anthony Fennell
Consultant or Advisory Role - Synta
Honoraria - Synta
Research Funding - Synta
Glenwood D. Goss
Consultant or Advisory Role - Synta (U)
Mark A. Socinski
Honoraria - Synta
Research Funding - Synta
Kazuhiko Nakagawa
Honoraria - Synta
Joan H. Schiller
Research Funding - Synta
Philip Bonomi
Consultant or Advisory Role - Synta (U)
Honoraria - Synta
Vera Hirsh
No relevant relationships to disclose
Karen Kelly
No relevant relationships to disclose
James F. Spicer
Research Funding - Guys and St. Thomas Hospital
Rafael Rosell
No relevant relationships to disclose
Bojan Zaric
Consultant or Advisory Role - Synta
Honoraria - Synta
Other Remuneration - Synta
Tudor-Eliade Ciuleanu
No relevant relationships to disclose
Vojislav M. Vukovic
Employment or Leadership Position - Synta
Stock Ownership - Synta
Florentina Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
Iman El-Hariry
Employment or Leadership Position - Synta
Stock Ownership - Synta
Wei Guo
Employment or Leadership Position - Synta
Stock Ownership - Synta
Suresh S. Ramalingam
Consultant or Advisory Role - Synta (U)